WSH in the News

Is It Time To Sell Gilead Sciences?

Patent Case Against Gilead Reopened; Result Could Remove Share Overhang

If GILD is successful in reducing this case's judgment or having it dismissed, it would remove some of the overhang affecting the share price...

Mednax: Profiting From Continuing Consolidation In The Healthcare Sector

A Few Key Points I Am Focusing On From Gilead Sciences' Upcoming Earnings Release

GILD's first-quarter earnings release [on 4/28, confirmed by Wall Street Horizon on 4/4] remains the most widely anticipated event of the quarter...

Data-as-a-Service Analytics Startup Kyper Taps WSH for Events Data

Kyper has incorporated content from Wall Street Horizon into its platform, to allow users to consider events data alongside other sources to create predictive signals based on historical analysis.

Updating My Outlook On Pfizer In Light Of The Recent Termination Of The Allergan Merger

See how corporate events such as upcoming the earnings announcement affect the outlook for PFE..

Regeneron Pharmaceuticals Is My Top Pick In The Biotech Space

Article includes shapshot of corporate event data from Wall Street Horizon as it factors into the analysis of REGN...

My Thoughts On Gilead Sciences' Patent Loss

How will Gilead's forthcoming earnings release impact the share price? Check out Seeking Alpha's detailed analysis...